Clinical Malaria

The Clinical Malaria Group conducts blood-stage controlled human malaria infection (CHMI) studies in healthy volunteers to evaluate the safety and efficacy of candidate anti-malarials.

Bridget Barber

Associate Professor Bridget Barber

Group Leader

Malaria infection in blood cells

Research Focus

The controlled human malaria infection (CHMI) model has been used to evaluate >10 investigational medicinal products. Models have been established for an artemisinin-sensitive and an artemisinin-resistant P. falciparum strain and other Plasmodium species including P. vivax, P. malariae, and P. knowlesi. The model has also enabled the conduct of studies to evaluate transmission-blocking interventions and has enabled the conduct of exploratory studies to evaluate immunological and pathophysiological response to infection.

Gallery

The Clinical Malaria lab
Blood samples
The Clinical Malaria team

Research Projects

Current Research Projects

Clinical trials to evaluate candidate anti-malarials.

Using the IBSM model to improve understanding of the pathogenesis of malaria.


Research Team

Adam Potter

Arya SheelaNair

Azrin Rahman

Fiona Amante

Fiona Amante


Funding

  • Clinical trials to evaluate candidate anti-malarials.
  • The Bill and Melinda Gates Foundation.

Publications

Transmission blocking activity of low-dose Tafenoquine in healthy volunteers experimentally infected with Plasmodium falciparum.

Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum

Read more